SNPMiner Trials by Shray Alag

SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT01299337

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

The purpose of this study is: - To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. - To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. - To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. - To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).

NCT01299337 Depression

1 Interventions

Name: T3

Description: Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.

Type: Drug


Primary Outcomes

Measure: To determine if people get better faster and stay better longer using T3 as adjunct to ECT.

Time: Phase A and Phase B

Time Perspective: Retrospective


There is one SNP


1 C785T

The DI-C785T allele will be associated with lower T3 levels at baseline and faster treatment response. --- C785T ---

HPO Nodes